Abivax Nov 22, 2026 Copy link Abivax Statement on Short Seller Report Abivax Statement on Short Seller Report PARIS, France – November 20, 2026 – 10:30 PM CET – Abivax SA (Euronext Paris: Business
Abivax Nov 2, 2026 Copy link Abivax to Participate in Upcoming Fall Investor Conferences Abivax to Participate in Upcoming Fall Investor Conferences PARIS, France – November 2, 2026 – 10:05 PM CET – Abivax Business
Abivax Sep 30, 2026 Copy link Abivax to Present Data on Obefazimod at United European Gastroenterology (UEG) Week 2026 Abivax to Present Data on Obefazimod at United European Gastroenterology (UEG) Week 2026 Four oral presentations and Business
Abivax Sep 21, 2026 Copy link Abivax Presents Business Updates and First Half 2026 Financial Results Abivax Presents Business Updates and First Half 2026 Financial Results Chris Rabbat to succeed Fabio Cataldi as Chief Business
Abivax Jul 30, 2026 Copy link Abivax Announces Positive Pre-NDA Interaction with the FDA for Obefazimod Abivax Announces Positive Pre-NDA Interaction with the FDA for Obefazimod Company remains on track to submit its first Business
Abivax Jul 23, 2026 Copy link Abivax Strengthens Commercial Capabilities With Strategic Leadership Appointments Abivax Strengthens Commercial Capabilities With Strategic Leadership Appointments Appointed industry leaders bring Business
Abivax Jun 2, 2026 Copy link Abivax Announces Landmark Phase 3 ABTECT Maintenance Trial Results Evaluating Obefazimod in Moderately to Severely Active Ulcerative Colitis Abivax Announces Landmark Phase 3 ABTECT Maintenance Trial Results Evaluating Obefazimod in Moderately to Severely Business
Abivax May 26, 2026 Copy link Abivax Presents First Quarter 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a Phase 2a/2b Open-Label Extension Trial of Obefazimod Following Dose De-Escalation in Patients with Ulcerative Colitis Abivax Presents First Quarter 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a Phase 2a/2b Business